High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults.

Publication date: Apr 01, 2024

We assessed the relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) in preventing respiratory or cardiovascular hospitalizations in older adults. FinFluHD was a phase 3b/4 modified double-blind, randomized pragmatic trial. Enrolment of 121,000 adults ≥65 years was planned over three influenza seasons (October to December 2019-2021). Participants received a single injection of QIV-HD or QIV-SD. The primary endpoint was first occurrence of an unscheduled acute respiratory or cardiovascular hospitalization (ICD-10 primary discharge J/I codes), from ≥14 days post-vaccination until May 31. The study was terminated after one season due to COVID-19; follow-up data for 2019-2020 are presented. 33,093 participants were vaccinated (QIV-HD, n = 16,549; QIV-SD, n = 16,544); 529 respiratory or cardiovascular hospitalizations (QIV-HD, n = 257; QIV-SD, n = 272) were recorded. The rVE of QIV-HD versus QIV-SD to prevent respiratory/cardiovascular hospitalizations was 5. 5% (95% CI, -12. 4 to 20. 7). When prevention of respiratory and cardiovascular hospitalizations were considered separately, rVE estimates of QIV-HD versus QIV-SD were 5. 4% (95% CI, -28. 0 to 30. 1) and 7. 1% (95% CI, -15. 0 to 25. 0), respectively. Serious adverse reactions were

Concepts Keywords
Hospitalizations cardiovascular hospitalization
Influenza pragmatic vaccine trial
respiratory hospitalization


Type Source Name
disease VO dose
disease MESH Influenza
disease VO vaccine
disease VO vaccine effectiveness
disease VO injection
disease VO vaccination
disease MESH COVID-19
disease VO vaccinated

Original Article

(Visited 1 times, 1 visits today)